Genentech secures FDA breakthrough therapy designation for Gazyva
US-based biotechnology company Genentech announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for Gazyva (obinutuzumab) used in treating adults with lupus